Using AI to Create Better, More Potent Medicines

While it can take years for the pharmaceutical industry to create medicines capable of treating or curing human disease, a new study suggests that using generative artificial intelligence could vastly accelerate the drug-development process.

Today, most drug discovery is carried out by human chemists who rely on their knowledge and experience to select and synthesize the right molecules needed to become the safe and efficient medicines we depend on. To identify the synthesis paths, scientists often employ a technique called retrosynthesis - a method for creating potential drugs by working backward from the wanted molecules and searching for chemical reactions to make them.

Yet because sifting through millions of potential chemical reactions can be an extremely challenging and time-consuming endeavor, researchers at The Ohio State University have created an AI framework called G2Retro to automatically generate reactions for any given molecule. The new study showed that compared to current manual-planning methods, the framework was able to cover an enormous range of possible chemical reactions as well as accurately and quickly discern which reactions might work best to create a given drug molecule.

"Using AI for things critical to saving human lives, such as medicine, is what we really want to focus on," said Xia Ning, lead author of the study and an associate professor of computer science and engineering at Ohio State. "Our aim was to use AI to accelerate the drug design process, and we found that it not only saves researchers time and money but provides drug candidates that may have much better properties than any molecules that exist in nature."

This study builds on previous research of Ning’s where her team developed a method named Modof that was able to generate molecule structures that exhibited desired properties better than any existing molecules. "Now the question becomes how to make such generated molecules, and that is where this new study shines," said Ning, also an associate professor of biomedical informatics in the College of Medicine.

The study was published today in the journal Communications Chemistry.

Ning's team trained G2Retro on a dataset that contains 40,000 chemical reactions collected between 1976 and 2016. The framework "learns" from graph-based representations of given molecules, and uses deep neural networks to generate possible reactant structures that could be used to synthesize them. Its generative power is so impressive that, according to Ning, once given a molecule, G2Retro could come up with hundreds of new reaction predictions in only a few minutes.

"Our generative AI method G2Retro is able to supply multiple different synthesis routes and options, as well as a way to rank different options for each molecule," said Ning. "This is not going to replace current lab-based experiments, but it will offer more and better drug options so experiments can be prioritized and focused much faster."

To further test the AI's effectiveness, Ning’s team conducted a case study to see if G2Retro could accurately predict four newly released drugs already in circulation: Mitapivat, a medication used to treat hemolytic anemia; Tapinarof, which is used to treat various skin diseases; Mavacamten, a drug to treat systemic heart failure; and Oteseconazole, used to treat fungal infections in females. G2Retro was able to correctly generate exactly the same patented synthesis routes for these medicines, and provided alternative synthesis routes that are also feasible and synthetically useful, Ning said.

Having such a dynamic and effective device at scientists' disposal could enable the industry to manufacture stronger drugs at a quicker pace - but despite the edge AI might give scientists inside the lab, Ning emphasizes the medicines G2Retro or any generative AI creates still need to be validated - a process that involves the created molecules being tested in animal models and later in human trials.

"We are very excited about generative AI for medicine, and we are dedicated to using AI responsibly to improve human health," said Ning.

Chen Z, Ayinde OR, Fuchs JR, Sun H, Ning X.
G2Retro as a two-step graph generative models for retrosynthesis prediction.
Commun Chem. 2023 May 30;6(1):102. doi: 10.1038/s42004-023-00897-3

Most Popular Now

Philips Foundation 2024 Annual Report: E…

Marking its tenth anniversary, Philips Foundation released its 2024 Annual Report, highlighting a year in which the Philips Foundation helped provide access to quality healthcare for 46.5 million people around...

New AI Transforms Radiology with Speed, …

A first-of-its-kind generative AI system, developed in-house at Northwestern Medicine, is revolutionizing radiology - boosting productivity, identifying life-threatening conditions in milliseconds and offering a breakthrough solution to the global radiologist...

Scientists Argue for More FDA Oversight …

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical...

New Research Finds Specific Learning Str…

If data used to train artificial intelligence models for medical applications, such as hospitals across the Greater Toronto Area, differs from the real-world data, it could lead to patient harm...

Giving Doctors an AI-Powered Head Start …

Detection of melanoma and a range of other skin diseases will be faster and more accurate with a new artificial intelligence (AI) powered tool that analyses multiple imaging types simultaneously...

AI Agents for Oncology

Clinical decision-making in oncology is challenging and requires the analysis of various data types - from medical imaging and genetic information to patient records and treatment guidelines. To effectively support...

Patients say "Yes..ish" to the…

As artificial intelligence (AI) continues to be integrated in healthcare, a new multinational study involving Aarhus University sheds light on how dental patients really feel about its growing role in...

Brains vs. Bytes: Study Compares Diagnos…

A University of Maine study compared how well artificial intelligence (AI) models and human clinicians handled complex or sensitive medical cases. The study published in the Journal of Health Organization...

'AI Scientist' Suggests Combin…

An 'AI scientist', working in collaboration with human scientists, has found that combinations of cheap and safe drugs - used to treat conditions such as high cholesterol and alcohol dependence...

Start-ups in the Spotlight at MEDICA 202…

17 - 20 November 2025, Düsseldorf, Germany. MEDICA, the leading international trade fair and platform for healthcare innovations, will once again confirm its position as the world's number one hotspot for...